The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry

Andrea R. Masters, Christopher J. Sweeney, David R. Jones

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

An accurate and precise method was developed using HPLC-MS/MS to quantify erlotinib (OSI-774) and its O-desmethyl metabolite, OSI-420, in plasma. The advantages of this method include the use of a small sample volume, liquid-liquid extraction with high extraction efficiency and short chromatographic run times. The analytes were extracted from 100 μL plasma volume using hexane:ethyl acetate after midazolam was added to the sample for internal standardization. The compounds were separated on a Phenomenex C-18 Luna analytical column with acetonitrile:5 mM ammonium acetate as the mobile phase. All compounds were monitored by tandem mass spectrometry with electrospray positive ionization. The intra-day accuracy and precision (% coefficient of variation, % CV) estimates for erlotinib at 10 ng/mL were 90% and 9%, respectively. The intra-day accuracy and precision estimates for OSI-420 at 5 ng/mL were 80% and 4%, respectively. This method was used to quantify erlotinib and OSI-420 in plasma of patients (n = 21) administered 150 mg erlotinib per day for non-small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)379-383
Number of pages5
JournalJournal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume848
Issue number2
DOIs
StatePublished - Apr 1 2007

Keywords

  • Erlotinib
  • HPLC-MS/MS
  • OSI-774

ASJC Scopus subject areas

  • Biochemistry

Fingerprint Dive into the research topics of 'The quantification of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry'. Together they form a unique fingerprint.

  • Cite this